Yehyun Park1, Jae Hee Cheon2. 1. Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea. 2. Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea. geniushee@yuhs.ac.
Abstract
PURPOSE OF REVIEW: The treatment of intestinal Behcet's disease (BD) is challenging, and one-third of patients require surgery due to failure of conventional therapies. Anti-tumor necrosis factor-α (TNF-α) and other new biologics have been actively investigated for managing intestinal BD. In this article, we review the updated experiences and up-to-date clinical data on anti-TNF-α and other biologics for the management of intestinal BD. RECENT FINDINGS: Recent prospective studies have proved the efficacy and safety of infliximab and adalimumab for treating intestinal BD. Recent studies with other biologics such as anti-interleukin (IL)-1 (anakinra and canakinumab) and anti-IL-6 (tocilizumab) have shown promising results in patients with systemic, including intestinal, BD. Both infliximab and adalimumab can be useful in managing patients with intestinal BD, especially severe or refractory cases, with a similar efficacy and safety profile. More evidence for anakinra, canakinumab, tocilizumab, anti-IL-17 (secukinumab), and anti-IL-12/23 (ustekinumab) in intestinal BD is required.
PURPOSE OF REVIEW: The treatment of intestinal Behcet's disease (BD) is challenging, and one-third of patients require surgery due to failure of conventional therapies. Anti-tumornecrosis factor-α (TNF-α) and other new biologics have been actively investigated for managing intestinal BD. In this article, we review the updated experiences and up-to-date clinical data on anti-TNF-α and other biologics for the management of intestinal BD. RECENT FINDINGS: Recent prospective studies have proved the efficacy and safety of infliximab and adalimumab for treating intestinal BD. Recent studies with other biologics such as anti-interleukin (IL)-1 (anakinra and canakinumab) and anti-IL-6 (tocilizumab) have shown promising results in patients with systemic, including intestinal, BD. Both infliximab and adalimumab can be useful in managing patients with intestinal BD, especially severe or refractory cases, with a similar efficacy and safety profile. More evidence for anakinra, canakinumab, tocilizumab, anti-IL-17 (secukinumab), and anti-IL-12/23 (ustekinumab) in intestinal BD is required.
Entities:
Keywords:
Behcet’s disease; Gastrointestinal Behcet’s disease; Small bowel
Authors: J A M van Laar; T Missotten; P L A van Daele; A Jamnitski; G S Baarsma; P M van Hagen Journal: Ann Rheum Dis Date: 2006-11-23 Impact factor: 19.103
Authors: Gulen Hatemi; Robin Christensen; Dongsik Bang; Bahram Bodaghi; Aykut Ferhat Celik; Farida Fortune; Julien Gaudric; Ahmet Gul; Ina Kötter; Pietro Leccese; Alfred Mahr; Robert Moots; Yesim Ozguler; Jutta Richter; David Saadoun; Carlo Salvarani; Francesco Scuderi; Petros P Sfikakis; Aksel Siva; Miles Stanford; Ilknur Tugal-Tutkun; Richard West; Sebahattin Yurdakul; Ignazio Olivieri; Hasan Yazici Journal: Ann Rheum Dis Date: 2018-04-06 Impact factor: 19.103